The adeno-associated viral vector market is anticipated to grow at a CAGR of more than 10% by 2035, claims Roots Analysis

Given their low immunogenicity, diversified targets and ability to offer higher biosafety, the adeno-associated viral vectors are actively being evaluated for the development of various therapies for the treatment of chronic diseases and infections.

For additional details, please visit or email [email protected]